Caution:At present, there are occasional discrepancies in the display of intellectual property rights holders and their representatives. We are working on a solution.
see.ip - Details for SYNERGISTISCHE ANTITUMORWIRKUNG EINES BCL-2-INHIBITORS IN KOMBINATION MIT RITUXIMAB UND/ODER BENDAMUSTIN ODER EINES BCL-2-INHIBITORS IN KOMBINATION MIT CHOP
Details for 2019845466
Up to date per 12.06.2026
Actions
Details for 2019845466
Title / Product Name
SYNERGISTISCHE ANTITUMORWIRKUNG EINES BCL-2-INHIBITORS IN KOMBINATION MIT RITUXIMAB UND/ODER BENDAMUSTIN ODER EINES BCL-2-INHIBITORS IN KOMBINATION MIT CHOP
Status
Deleted
Protection Type
European Patent
(AT-) Application Number
2019845466
EP Publication Number
3672591
E-Number
1656467
Language
EN
PCT Number
CN19097028
Publication Date
01.07.2020 A
14.02.2024 B1
Registration Date
14.02.2024
AT Publication Date
15.03.2024
Application Date
22.07.2019
Registration Number
-
Priorities
31.07.2018
CN
201810867252
IPC
A61K 31/4184 20060101AFI20230904BHEP
Maximum Duration of Protection
22.07.2039
Owner
Ascentage Pharma (Suzhou) Co., Ltd.Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park Suzhou, Jiangsu 215000CN
Representative
No representatives present
Inventor
YANG, DajunUnit 701, Building B7, 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000CN
ZHAI, YifanUnit 701, Building B7, 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000CN
WANG, GuangfengUnit 701, Building B7, 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000CN